Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

Here are the injectable drugs: Wegovy, Ozempic, Semaglutide and Zepbound that we will evaluate in this study. Wegovy: Wegovy is a prescription medication used for weight loss in adults with obesity or ...

and gives Lilly more firepower as it seeks to gain wider insurance coverage in an obesity drug market estimated to reach more than $150 billion annually by the next decade. Zepbound helped nearly ...

Zepbound reporting losing more weight than Novo Nordisk's (NVO) Wegovy GLP-1 weight-loss drug. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.